Submission Deadline: Dec. 10, 2019

This special issue currently is open for paper submission and guest editor application.

Join as Guest Editor Submit to Special Issue
Lead Guest Editor
Anil Tombak
Department of Internal Medicine, Mersin University, Mersin, Turkey
Guest Editors
  • Elif Birtas Atesoglu
    Anadolu Saglik Merkezi,  Kocaeli, Turkey
  • Mahmut Yeral
    Baskent University, Ankara, Turkey
  • Ozgur Mehtap
    Kocaeli University, Kocaeli, Turkey
  • Demircan Ozbalci
    Suleyman Demirel University, Almaty, Turkey
  • Gökhan Özgür
    Department of Hematology, Ankara, Turkey
  • Fusun Gediz
    Bozyaka Research and Training Hospital, Izmir, Turkey
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
Published Papers
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.

Special Issue Flyer (PDF)

Please download to know all details of the
Special Issue

Lymphomas consists of a diverse group of malignant neoplasms. They derived from B cell progenitors, T cell progenitors, mature B cells, mature T cells, or natural killer cells. The World Health Organization (WHO) classifies tumors of the hematopoietic and lymphoid tissues according to their morphologic, immunophenotypic, genetic, and clinical features and this classification was revised in 2016. The pathogenesis of lymphomas still continues to dissolve and new biological subtypes are identified, and new information is added. These developments and changes bring new suggestions for the diagnostic, prognostic evaluation and treatment of lymphomas. A large number of new agents were introduced for the the treatment of lymphomas in the last 20 years. New monoclonal antibodies and targeted agents acting on each of its specific mechanisms have been successfully applied to different lymphoma subtypes. In addition, phase studies of many agents are still ongoing, and the introduction of a significant number of patients into these studies is a necessity in today's lymphoma treatment practice.

Aims and Scope:

  1. Lymphoma
  2. Chemotherapy
  3. Antibodies
  4. Biology
  5. Small molecules
  6. Molecular pathogenesis
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186